CS182991A3 - Aminobenzodiazepines, process of their preparation and medicaments based thereon - Google Patents

Aminobenzodiazepines, process of their preparation and medicaments based thereon Download PDF

Info

Publication number: CS182991A3
Authority: CS; Czechoslovakia
Prior art keywords: infections; hiv; formula; compound; cells
Prior art date: 1990-06-18

Application number

CS911829A

Other languages

Czech (cs)

English (en)

Inventor

Anne Roberte Bellemin

James Valentine Early

Ming-Chu Hsu

Steve Yik-Kai Tam

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-18

Filing date

1991-06-14

Publication date

1992-04-15

1991-06-14 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1992-04-15 Publication of CS182991A3 publication Critical patent/CS182991A3/cs

Links

239000003814 drug Substances 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 8
NDNQCTVYOKEYIV-UHFFFAOYSA-N 1h-1,2-benzodiazepin-3-amine Chemical class C1=CC(N)=NNC2=CC=CC=C21 NDNQCTVYOKEYIV-UHFFFAOYSA-N 0.000 title claims description 5
238000000034 method Methods 0.000 title claims description 4
230000008569 process Effects 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims description 43
208000031886 HIV Infections Diseases 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 7
206010038997 Retroviral infections Diseases 0.000 claims description 5
208000036142 Viral infection Diseases 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
230000009385 viral infection Effects 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
239000004615 ingredient Substances 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
-1 7-chloro-N-methyl-5- (1H-pyrrol-2-yl) -3H-1,4-benzodiazole-2-amine Chemical compound 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
229940049706 benzodiazepine Drugs 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
210000004027 cell Anatomy 0.000 description 22
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
230000000694 effects Effects 0.000 description 15
239000000243 solution Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 13
239000000203 mixture Substances 0.000 description 12
229940126062 Compound A Drugs 0.000 description 11
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000003826 tablet Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000014509 gene expression Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
230000036436 anti-hiv Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
241000220479 Acacia Species 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102100020873 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
XWNMORIHKRROGW-UHFFFAOYSA-N Ro 5-3335 Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CN1 XWNMORIHKRROGW-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
238000001890 transfection Methods 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
XRUJJHXKFULRSH-UHFFFAOYSA-N 1,2-benzodiazepine-3-thione Chemical compound N1=NC(=S)C=CC2=CC=CC=C21 XRUJJHXKFULRSH-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
KDBPYQKBOVPKGL-UHFFFAOYSA-N 3-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine Chemical compound N1C(=CC=C1)C1C(=NC2=C(C=N1)C=CC=C2)N KDBPYQKBOVPKGL-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
RCJNCEREGNKOCQ-UHFFFAOYSA-N 7-chloro-5-(1h-pyrrol-2-yl)-3h-1,4-benzodiazepin-2-amine Chemical compound N=1CC(N)=NC2=CC=C(Cl)C=C2C=1C1=CC=CN1 RCJNCEREGNKOCQ-UHFFFAOYSA-N 0.000 description 1
LEAKQIXYSHIHCW-UHFFFAOYSA-N 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine Chemical compound N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CN1 LEAKQIXYSHIHCW-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000031504 Asymptomatic Infections Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229940122440 HIV protease inhibitor Drugs 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
BFVJJLKAJHGXGA-UHFFFAOYSA-J [Cl-].[Cl-].[Cl-].[Cl-].Cl.Cl.Cl.Cl.[Ti+4] Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].Cl.Cl.Cl.Cl.[Ti+4] BFVJJLKAJHGXGA-UHFFFAOYSA-J 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
NZMKIFMOEMHAFW-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl NZMKIFMOEMHAFW-UHFFFAOYSA-N 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000003607 modifier Substances 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008213 purified water Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000002544 virustatic Substances 0.000 description 1
230000001790 virustatic effect Effects 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CS911829A 1990-06-18 1991-06-14 Aminobenzodiazepines, process of their preparation and medicaments based thereon CS182991A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/539,500 US5141735A (en)	1990-06-18	1990-06-18	Substituted amino-benzodiazepines having anitviral activity

Publications (1)

Publication Number	Publication Date
CS182991A3 true CS182991A3 (en)	1992-04-15

Family

ID=24151485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS911829A CS182991A3 (en)	1990-06-18	1991-06-14	Aminobenzodiazepines, process of their preparation and medicaments based thereon

Country Status (21)

Country	Link
US (1)	US5141735A (is)
EP (1)	EP0462522A1 (is)
JP (1)	JPH04230280A (is)
KR (1)	KR920000746A (is)
CN (1)	CN1057462A (is)
AU (1)	AU7846991A (is)
BR (1)	BR9102489A (is)
CA (1)	CA2044694A1 (is)
CS (1)	CS182991A3 (is)
FI (1)	FI912927L (is)
HU (1)	HUT58069A (is)
IE (1)	IE912061A1 (is)
IL (1)	IL98499A0 (is)
IS (1)	IS3718A7 (is)
LT (1)	LTIP863A (is)
MC (1)	MC2263A1 (is)
MX (1)	MX26267A (is)
NO (1)	NO912346L (is)
NZ (1)	NZ238552A (is)
PT (1)	PT98007A (is)
ZA (1)	ZA914202B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07504654A (ja) *	1992-03-11	1995-05-25	ナルヘックス　リミテッド	オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US6071895A (en) *	1992-03-11	2000-06-06	Narhex Limited	Polar-substituted hydrocarbons
ATE253050T1 (de)	1992-03-11	2003-11-15	Narhex Ltd	Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US5888992A (en) *	1992-03-11	1999-03-30	Narhex Limited	Polar substituted hydrocarbons
SI9300288A (sl) *	1992-06-16	1993-12-31	Hoffmann La Roche	Benzodiazepini
JPH08502966A (ja) *	1992-10-23	1996-04-02	ユニバーシティー・オブ・マサチューセッツ・メディカル・センター	Ｒｎａ／リガンド結合の低分子抑制
US5939430A (en) *	1993-02-22	1999-08-17	Merrell Pharmaceuticals Inc.	Combinations of retroviral inhibitors
US5578573A (en) *	1995-01-20	1996-11-26	Houghten Pharmaceuticals, Inc.	Viral integrase inhibiting peptides
PT935417E (pt) *	1996-10-16	2009-07-17	Napo Pharmaceuticals Inc	Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina
US7015212B1 (en)	1999-05-12	2006-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Thiazepine inhibitors of HIV-1 integrase
GB0015904D0 (en) *	2000-06-28	2000-08-23	Hoffmann La Roche	Inhibitors of HPV E1 helicase enzyme
CN1527721A (zh) *	2000-09-12	2004-09-08	基因特罗生物治疗公司	含治疗性蛋白混合物的组合物及其生产方法
US20020150541A1 (en) *	2000-09-12	2002-10-17	Gene Trol Biotherapeutics, Inc.	Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) *	2000-09-12	2003-07-10	Lau Allan S.	Compositions comprising mixtures of therapeutic proteins and methods of producing the same
JP2005089298A (ja) *	2001-09-18	2005-04-07	Japan Tobacco Inc	ナフタレン化合物及びその医薬用途
JP2005508935A (ja) *	2001-10-05	2005-04-07	インターミューンインコーポレイテッド	肝線維症およびｃ型肝炎ウイルス感染症を治療する方法
CA2536041A1 (en) *	2003-11-10	2005-05-26	Angiotech International Ag	Medical implants and fibrosis-inducing agents
KR100652975B1 (ko) *	2005-03-17	2006-12-01	유해일	옥수숫대 반화학 기계펄프의 제조방법
US9446048B2 (en)	2011-03-17	2016-09-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins
JP7139323B2 (ja) *	2016-11-01	2022-09-20	エフ．ホフマン－ラロシュアーゲー	Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
WO2018093797A1 (en)	2016-11-15	2018-05-24	The Schepens Eye Research Institute, Inc.	Compositions and methods for the treatment of aberrant angiogenesis
WO2019099595A1 (en)	2017-11-14	2019-05-23	The Schepens Eye Research Institute, Inc.	NANO-EMULSION OF CBFβ-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY
EP3710008A4 (en)	2017-11-14	2021-08-25	The Schepens Eye Research Institute, Inc.	RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3267110A (en) *	1960-06-03	1966-08-16	Smith Kline French Lab	Trifluoromethyl substituted o-aminophenyl ketones
NL122319C (is) *	1961-06-20
NL295083A (is) *	1962-07-10
US3330481A (en) *	1965-03-18	1967-07-11	Filtra Inc	Dispersant dispenser of an absorbent or adsorbent material
CH502354A (de) *	1967-03-08	1971-01-31	Hoffmann La Roche	Verfahren zur Herstellung von Benzodiazepin-Derivaten
ZA698792B (en) *	1968-12-30	1971-03-31	Fujisawa Pharmaceutical Co	Novel antibiotic and derivatives and production thereof
JPS4843755B1 (is) *	1969-06-26	1973-12-20
US3778433A (en) *	1969-04-18	1973-12-11	Sumitomo Chemical Co	Process for producing benzodiazepine derivatives
US3954728A (en) *	1972-07-13	1976-05-04	Hoffman-La Roche Inc.	Preparation of triazolo benzodiazepines and novel compounds
DE3619202A1 (de) *	1986-06-07	1987-12-10	Merz & Co Gmbh & Co	Verwendung von avaron und avarol sowie von derivaten davon zur bekaempfung von aids und arc
US4788181A (en) *	1986-09-29	1988-11-29	The United States Of America As Represented By The Department Of Health And Human Services	5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
GB8806449D0 (en) *	1988-03-18	1988-04-20	Janssen Pharmaceutica Nv	Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones

1990
- 1990-06-18 US US07/539,500 patent/US5141735A/en not_active Expired - Fee Related
1991
- 1991-06-03 ZA ZA914202A patent/ZA914202B/xx unknown
- 1991-06-14 EP EP91109785A patent/EP0462522A1/en not_active Ceased
- 1991-06-14 CA CA002044694A patent/CA2044694A1/en not_active Abandoned
- 1991-06-14 NZ NZ238552A patent/NZ238552A/xx unknown
- 1991-06-14 IS IS3718A patent/IS3718A7/is unknown
- 1991-06-14 IL IL98499A patent/IL98499A0/xx unknown
- 1991-06-14 CS CS911829A patent/CS182991A3/cs unknown
- 1991-06-15 JP JP3168954A patent/JPH04230280A/ja active Pending
- 1991-06-17 CN CN91104342A patent/CN1057462A/zh active Pending
- 1991-06-17 HU HU912005A patent/HUT58069A/hu unknown
- 1991-06-17 IE IE206191A patent/IE912061A1/en unknown
- 1991-06-17 KR KR1019910009943A patent/KR920000746A/ko not_active Withdrawn
- 1991-06-17 FI FI912927A patent/FI912927L/fi not_active Application Discontinuation
- 1991-06-17 BR BR919102489A patent/BR9102489A/pt unknown
- 1991-06-17 NO NO91912346A patent/NO912346L/no unknown
- 1991-06-17 MC MC912193A patent/MC2263A1/fr unknown
- 1991-06-17 PT PT98007A patent/PT98007A/pt not_active Application Discontinuation
- 1991-06-17 AU AU78469/91A patent/AU7846991A/en not_active Abandoned
- 1991-06-17 MX MX2626791A patent/MX26267A/es unknown
1993
- 1993-08-16 LT LTIP863A patent/LTIP863A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
FI912927A7 (fi)	1991-12-19
US5141735A (en)	1992-08-25
NO912346D0 (no)	1991-06-17
IE912061A1 (en)	1991-12-18
EP0462522A1 (en)	1991-12-27
HUT58069A (en)	1992-01-28
IL98499A0 (en)	1992-07-15
KR920000746A (ko)	1992-01-29
PT98007A (pt)	1992-03-31
MX26267A (es)	1993-09-01
AU7846991A (en)	1992-01-02
JPH04230280A (ja)	1992-08-19
ZA914202B (en)	1992-03-25
MC2263A1 (fr)	1993-04-26
CA2044694A1 (en)	1991-12-19
BR9102489A (pt)	1992-01-21
IS3718A7 (is)	1991-12-19
FI912927A0 (fi)	1991-06-17
NO912346L (no)	1991-12-19
LTIP863A (en)	1995-03-27
NZ238552A (en)	1993-08-26
FI912927L (fi)	1991-12-19
HU912005D0 (en)	1991-12-30
CN1057462A (zh)	1992-01-01

Publication	Publication Date	Title
CS182991A3 (en)	1992-04-15	Aminobenzodiazepines, process of their preparation and medicaments based thereon
US20070299059A1 (en)	2007-12-27	Compostions and methods relating to novel compounds and targets thereof
NO314936B1 (no)	2003-06-16	4,4-disubstituerte-3,4-dihydro-2(1H)-kinazolinoner, farmasöytiske sammensetninger, preparater og farmasöytiske sett til behandling av HIV-infeksjon, samt anvendelse av bestemte kinazolinoner for fremstilling av etfarmasöytisk preparat
SK279262B6 (sk)	1998-08-05	Protivírusová zmes, farmaceutický prostriedok s je
JPH04305578A (ja)	1992-10-28	ベンゾジアゼピン、その製造法、及び薬剤としての利用
US5026726A (en)	1991-06-25	Gossylic iminolactones and gossylic lactones and their anti-viral activities
CA2085367A1 (en)	1992-01-31	Hiv-transactivators to treat aids
CZ115893A3 (en)	1994-01-19	Benzodiazepines, process for preparing thereof and medicaments based thereon
CN100450487C (zh)	2009-01-14	作为细胞增殖拮抗剂和细胞分化诱导剂的逆转录酶非核苷抑制剂
Halliday et al.	1996	Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene
IE903879A1 (en)	1991-05-08	Use of a benzodiazepine and a phenylpyrrylketone derivative
CZ372792A3 (en)	1993-12-15	Pyrrolylbenzodiazepinones, processes of their preparation and medicaments based thereon
US5932570A (en)	1999-08-03	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
JP2911956B2 (ja)	1999-06-28	５，１１―ジヒドロ―６Ｈ―ピリド［２，３―ｂ］［１，４］ベンゾジアゼピン―６―オン及び―チオン並びに該化合物のＡＩＤＳの予防又は治療における使用法
EP0586632A1 (en)	1994-03-16	Benzodiazepinones and medicines containing them
US6451999B2 (en)	2002-09-17	1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a HIV protease inhibitor
US20050026910A1 (en)	2005-02-03	Method of treating viral diseases
SK122996A3 (en)	1997-05-07	Novel crystal forms of 1-£5-methanesulfonamidoindolyl-2- -carbonyl\|-4-£3-(1-methylethylamino)-2-pyridinyl\|piperazine
AU5165198A (en)	1998-05-29	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inh ibitors
SI9720071A (sl)	1999-12-31	1-(3-aminoindazol-5-il)-3-butil-ciklična sečnina, uporabna kot inhibitor proteaze HIV
JP2003503455A (ja)	2003-01-28	抗ウイルス治療
ITMI950811A1 (it)	1996-10-21	Pirrolobenzotiadiazepine e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
LT4676B (lt)	2000-07-25	1-(3-aminoindazol-5-il)-3-fenilmetil-cikliniai karbamidai, naudojami kaip živ proteazės inhibitoriai